Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Jiangsu Kanion Pharmaceutical Co.,Ltd.'s (SHSE:600557) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Jiangsu Kanion PharmaceuticalLtd's (SHSE:600557) stock increased significantly by 15% over the past three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals usually dictate market outcomes. Specifically, we decided to study Jiangsu Kanion PharmaceuticalLtd's ROE in this article.
大多數讀者已經意識到,江蘇康寧藥業有限公司(上海證券交易所代碼:600557)的股票在過去三個月中大幅上漲了15%。我們想知道公司的財務狀況在價格變動中是否起着什麼作用,因爲公司的長期基本面通常決定市場業績。具體而言,我們決定在本文中研究江蘇康寧藥業有限公司的投資回報率。
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
股本回報率或投資回報率是用於評估公司管理層利用公司資本效率的關鍵指標。簡而言之,它衡量公司相對於股東權益的盈利能力。
How To Calculate Return On Equity?
如何計算股本回報率?
The formula for return on equity is:
股本回報率的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益
So, based on the above formula, the ROE for Jiangsu Kanion PharmaceuticalLtd is:
因此,根據上述公式,江蘇卡尼恩製藥有限公司的投資回報率爲:
10% = CN¥551m ÷ CN¥5.5b (Based on the trailing twelve months to March 2024).
10% = 5.51億元人民幣 ÷ 55億元人民幣(基於截至2024年3月的過去十二個月)。
The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.10 in profit.
“回報” 是過去十二個月的利潤。將其概念化的一種方法是,公司每擁有1元人民幣的股東資本,就會獲得0.10元人民幣的利潤。
What Is The Relationship Between ROE And Earnings Growth?
投資回報率與收益增長之間有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。然後,我們能夠評估公司的收益增長潛力,具體取決於公司對這些利潤進行再投資或 “保留” 了多少及其有效性。假設其他一切保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。
Jiangsu Kanion PharmaceuticalLtd's Earnings Growth And 10% ROE
江蘇卡尼恩製藥有限公司的收益增長和10%的投資回報率
When you first look at it, Jiangsu Kanion PharmaceuticalLtd's ROE doesn't look that attractive. Although a closer study shows that the company's ROE is higher than the industry average of 7.7% which we definitely can't overlook. Yet, Jiangsu Kanion PharmaceuticalLtd has posted measly growth of 3.7% over the past five years. Remember, the company's ROE is quite low to begin with, just that it is higher than the industry average. Hence, this goes some way in explaining the low earnings growth.
當你第一次看時,江蘇康寧藥業有限公司的投資回報率看起來並不那麼吸引人。儘管一項更仔細的研究表明,該公司的投資回報率高於行業平均水平的7.7%,但我們絕對不能忽視。然而,江蘇康寧藥業有限公司在過去五年中僅實現了3.7%的微弱增長。請記住,公司的投資回報率一開始就很低,只是高於行業平均水平。因此,這在某種程度上解釋了低收益增長。
Next, on comparing with the industry net income growth, we found that Jiangsu Kanion PharmaceuticalLtd's reported growth was lower than the industry growth of 9.2% over the last few years, which is not something we like to see.
接下來,與行業淨收入增長進行比較時,我們發現江蘇Kanion PharmaceuticallLTD報告的增長低於過去幾年9.2%的行業增長,這不是我們希望看到的。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240510/0-7daa766622566ec44defb33c003ea5ef-0-10a530376f86d3d427bcb34227498ae0.png/big)
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. What is 600557 worth today? The intrinsic value infographic in our free research report helps visualize whether 600557 is currently mispriced by the market.
收益增長是股票估值的重要因素。無論如何,投資者應設法確定預期的收益增長或下降是否已計入其中。然後,這可以幫助他們確定股票是面向光明還是暗淡的未來。今天的600557值多少錢?我們的免費研究報告中的內在價值信息圖有助於可視化600557目前是否被市場錯誤定價。
Is Jiangsu Kanion PharmaceuticalLtd Making Efficient Use Of Its Profits?
江蘇卡尼恩製藥有限公司是否在有效利用其利潤?
Despite having a moderate three-year median payout ratio of 28% (implying that the company retains the remaining 72% of its income), Jiangsu Kanion PharmaceuticalLtd's earnings growth was quite low. So there could be some other explanation in that regard. For instance, the company's business may be deteriorating.
儘管三年派息率中位數爲28%(這意味着該公司保留了剩餘的72%的收入),但江蘇凱恩製藥有限公司的收益增長還是相當低的。因此,在這方面可能還有其他解釋。例如,該公司的業務可能正在惡化。
Additionally, Jiangsu Kanion PharmaceuticalLtd has paid dividends over a period of at least ten years, which means that the company's management is determined to pay dividends even if it means little to no earnings growth. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 31%. Still, forecasts suggest that Jiangsu Kanion PharmaceuticalLtd's future ROE will rise to 12% even though the the company's payout ratio is not expected to change by much.
此外,江蘇Kanion Pharmaceuticalltd已在至少十年內派發了股息,這意味着即使收益增長微乎其微,公司的管理層也決心派發股息。根據分析師的最新估計,我們發現該公司未來三年的派息率預計將穩定在31%。儘管如此,預測表明,江蘇Kanion Pharmaceuticalltd的未來投資回報率將上升至12%,儘管該公司的派息率預計不會有太大變化。
Summary
摘要
Overall, we feel that Jiangsu Kanion PharmaceuticalLtd certainly does have some positive factors to consider. However, while the company does have a decent ROE and a high profit retention, its earnings growth number is quite disappointing. This suggests that there might be some external threat to the business, that's hampering growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總的來說,我們認爲江蘇康寧藥業有限公司確實有一些積極的因素需要考慮。但是,儘管該公司的投資回報率確實不錯,利潤保留率很高,但其收益增長數字令人失望。這表明業務可能面臨一些外部威脅,這阻礙了增長。話雖如此,從分析師目前的估計來看,我們發現該公司的收益有望增強。要了解有關公司未來收益增長預測的更多信息,請查看這份關於分析師預測的免費報告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。